Search

Displaying results 5551 - 5560 of 7186 in total
  1. Drug

    Cyclopropane

    go.drugbank.com/drugs/DB13984
    Experimental

    Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene. … Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining stable hemodynamics. Its use was ultimately limited because it was highly explosive.

  2. Drug

    Tovecimig

    go.drugbank.com/drugs/DB30220
    Investigational

    NOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended

  3. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

  4. Drug

    Cositecan

    go.drugbank.com/drugs/DB05806
    Investigational

    It is used to treat cancer.

  5. Drug

    Altropane I-123

    go.drugbank.com/drugs/DB15144
    Investigational

    Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

  6. Drug

    ARCT-810

    go.drugbank.com/drugs/DB17683
    Investigational

    ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.

  7. Drug

    Perifosine

    go.drugbank.com/drugs/DB06641
    Investigational

    Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

  8. Drug

    1-benzylimidazole

    go.drugbank.com/drugs/DB04581
    Experimental

    1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.

  9. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  10. Drug

    KP1237

    go.drugbank.com/drugs/DB18401
    Experimental

    KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.